## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

1.      (Currently Amended) A method for treating proliferative skin diseases comprising the administration of an effective amount of a gel comprising about 0.01% to about 2% w/v tazarotene ~~gel~~ and:

(a) water;

 (b) edetate disodium;

(c) ascorbic acid;

(d) Carbomer 934P;

(e) Poloxamer 407;

(f) polyethylene glycol;

(g) Polysorbate 40;

(h) hexylene glycol;

(i) butylated hydroxytoluene;

(j) butylated hydroxyanisole;

(k) benzyl alcohol; and

(l) tromethamine

and  an effective amount of a corticosteroid, wherein said corticosteroid is alclometasone dipropionate and/or betamethasone valerate.

Claims 2-5.   (Cancelled)

6.      (Currently Amended) A method for treating psoriasis in a human subject by topically applying to the psoriatic skin of said subject an effective amount of  gel comprising about 0.01% to about 2% w/v tazarotene and:

(a) water;

 (b) edetate disodium;

(c) ascorbic acid;

(d) Carbomer 934P;

(e) Poloxamer 407;

(f) polyethylene glycol;

(g) Polysorbate 40;

(h) hexylene glycol;

(i) butylated hydroxytoluene;

(j) butylated hydroxyanisole;

(k) benzyl alcohol; and

(l) tromethamine

and an effective amount of a corticosteroid wherein said corticosteroid is alclometasone dipropionate and/or betamethasone valerate.

Claims 7-10. (Cancelled)

11.     (Previously Amended) The method of claim 6 wherein tazarotene is administered once daily in the evening and the corticosteroid is administered once daily in the morning.

12.     (Previously Amended) The method of Claim 6 wherein the tazarotene is applied as a 1.0 % gel.

13.     (Previously Amended) The method of Claim 6 wherein the tazarotene is applied as a 1.0 % cream.

14.     (Canceled)